Overview

* GeneDx Q2 2025 revenue rises 49% yr/yr to $102.7 mln

* Adjusted EPS beats analyst expectations, per LSEG data

* Co raises full-year revenue guidance to $400-$415 mln

Outlook

* GeneDx ( WGS ) raises 2025 revenue guidance to $400-$415 mln

* Company expects 48%-52% growth in exome and genome revenue

* GeneDx ( WGS ) anticipates 68%-71% adjusted gross margin for 2025

* Company sees positive adjusted net income each quarter in 2025

Result Drivers

* EXOME AND GENOME TESTING - Revenue from exome and genome tests grew 69% yr/yr, driven by increased adoption in pediatrics

* GROSS MARGIN EXPANSION - Adjusted gross margin improved to 71%, reflecting operational efficiencies

* AAP RECOMMENDATION - American Academy of Pediatrics' recommendation for exome and genome testing as first-tier tests boosted demand

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $0.5 $0.1 (5

Adjusted Analysts

EPS )

Q2 $15 mln

Adjusted

Net

Income

Q2 Net $10.80

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for GeneDx Holdings Corp ( WGS ) is $110.00, about 22.8% above its July 28 closing price of $84.91

* The stock recently traded at 54 times the next 12-month earnings vs. a P/E of 75 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)